ABL1 (F317I) NanoBRET Target Engagement Intracellular Kinase Assay for screening of compounds binding to the target.
ABL1 (F317I)
ABL1 (F317I)
ABL, JTK7, P150, c-ABL, v-ABL
HEK293 human epithelial cell line from ATCC
384-well plate format using Promega’s NanoBRET TE Intracellular Kinase Assay
HEK293 cells transiently expressing NanoLuc- ABL1 (F317I) Fusion Vector were seeded into the wells of 384-well plates. The cells were pre-treated with the NanoBRET Tracer K-4 and then treated with reference compound Dasatinib for 1 hour. The BRET signal was measured on an Envision 2104 Multilabel Reader. IC50 value was calculated and IC50 curve was plotted using the GraphPad Prism program based on a sigmoidal dose response equation.
Binding of compound to target kinase
Compounds | IC50 (M) |
---|---|
Dasatinib | 7.396e-09 |
Malvern, USA
![Reference compound IC50 for ABL1(F317I)](/wp-content/uploads/2023/11/ABL1_%28F317I%29_nano.png?itok=pbDp_he7)